<DOC>
	<DOCNO>NCT01773889</DOCNO>
	<brief_summary>This study test hypothesis add pegylated IFN ( IFN ) a-2b denileukin diftitox improve potential denileukin diftitox alone deplete regulatory T cell ( Tregs ) thereby boost tumor immunity patient advanced-stage epithelial ovarian cancer , enhance treatment efficacy .</brief_summary>
	<brief_title>A Trial Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A Stage III IV Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Able provide inform consent Not immunemodulating drug , except use denileukin diftitox premedication , unless principal investigator grant exception ( exception must document write ) Histologically prove epithelial ( nongerm cell , nonstromal cell ) cancer ovary , fallopian tube extraovarian peritoneal carcinoma . Clinical recurrence without documented pathology acceptable FIGO stage III IV fail prior firstline therapy , ineligible intolerant therapy Measurable disease define section 6 within 30 day study enrollment Blood hemoglobin ≥ 8.5 gm/dl within 7 day study enrollment Absolute neutrophil count ≥ 750/mm3 within 7 day study enrollment Platelet count ≥ 40,000/mm3 within 7 day study enrollment SGOT ( serum glutamic oxaloacetic transaminase ) ≤10 x upper limit normal within 7 day study enrollment Normal TSH ( thyroidstimulating hormone ) within 30 day study enrollment No chemotherapy 14 day prior radiation therapy thirty day prior initiation treatment study No concurrent chemotherapy , surgery radiation therapy protocol except surgery radiation therapy control symptom concurrence principal investigator No contraindication study treatment No active major medical problem , include untreated uncontrolled infection Beck Depression Index ≥15 within 30 day study enrollment If reproductive potential , negative urine pregnancy test within 3 day study enrollment , agreement use adequate contraception . Pregnancy test continue monthly treatment unless subject longer able become pregnant sufficient justification otherwise Not breast feed Life expectancy ≥ six month ECOG ( Eastern Cooperative Oncology Group ) performance status ≤ 2 Serum albumin ≥ 1.8 gm/dl Age ≥ 18 year Acceptable baseline retinal examination within 30 day study enrollment No active substance abuse prior 6 month Patients fail single agent denileukin diftitox ongoing trial `` A Phase II Trial Intravenous Ontak Treat Epithelial Ovarian Cancer FIGO Stage III Stage IV , Extraovarian Peritoneal Carcinoma , Failing Ineligible FirstLine Therapy '' eligible trial provide three week elapse since last denileukin diftitox infusion meet eligibility criterion successfully undergo screen examination trial . Unable tolerate phlebotomy Germ cell stromal cell cancer ovary , currently uncured cancer Active autoimmune disease include systemic lupus erythematosus , psoriasis , inflammatory bowel disease medically control Autoimmune hepatitis , whether medically control Contraindication study drug Known hypersensitivity denileukin diftitox , pegylated IFNα2a component excipients Current pregnancy breast feed Inability document adequate contraception female reproductive potential On immunemodulating drug , except denileukin diftitox premedications approve principal investigator Chemotherapy within 14 day radiation therapy within thirty day prior initiation study treatment Life expectancy less six month Serum albumin &lt; 1.8 gm/dl Blood hemoglobin &lt; 8.5 gm/dl ECOG performance status &gt; 2 Symptomatic coronary artery disease ( include uncontrolled angina , congestive heart failure , like ) Uncontrolled hypertension ( diastolic BP consistently &gt; 100 mm Hg systolic BP consistently &gt; 160 mm Hg regular basis ) Uncontrolled , symptomatic cardiac arrhythmia Retinopathy associate significant visual impairment Beck Depression Index &gt; 15 Active substance abuse prior 6 month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Epithelial Ovarian Cancer</keyword>
	<keyword>FIGO ( International Federation Gynecology Obstetrics ) Stage III Stage IV</keyword>
	<keyword>Extraovarian Peritoneal Cancer</keyword>
	<keyword>Fallopian Tube Carcinoma Failing</keyword>
</DOC>